Dendritic cell vaccine - SBI Biotech

Drug Profile

Dendritic cell vaccine - SBI Biotech

Alternative Names: Immunocell Therapy Project - SBI Biotech

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SBI Biotech
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma; Solid tumours

Most Recent Events

  • 24 Sep 2015 No recent reports of development identified - Phase-I/II for Malignant melanoma in Japan (SC)
  • 24 Sep 2015 No recent reports of development identified - Preclinical for Solid tumours in Japan (unspecified route)
  • 17 Aug 2012 SBI Biotech completes enrolment in its phase I/II trial for Malignant melanoma in Japan (UMIN000004617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top